Literature DB >> 29181268

The flip-flop fungus sign: an FDG PET/CT sign of benignity.

Alex A Nagelschneider1, Stephen M Broski1, William P Holland2, David E Midthun2, Anne-Marie Sykes1, Val J Lowe1, Patrick J Peller3, Geoffrey B Johnson1,4.   

Abstract

Benign granulomatous processes such as fungal infection may mimic metastatic lung cancer on FDG PET/CT. We found that these processes often have draining lymph node(s) with equal or greater FDG activity than associated lung nodule(s), a "flip-flop" of what is commonly seen in lung cancer. The aim of this study was to examine the utility of this "flip-flop fungus" (FFF) sign for diagnosing benign pulmonary disease. FDG PET/CT scans performed between 9/09-3/13 for the indications of pulmonary nodule or mass were reviewed. Scans with at least one hilar or mediastinal FDG avid draining node were included. Patients with a history of cancer, lack of pathologic confirmation, or without at least two years of imaging follow-up were excluded. A total of 209 FDG PET/CT exams were included and reviewed in a blinded fashion. A positive FFF sign had a sensitivity of 60.0% (95% CI: 47.6-71.5%) and specificity of 84.9% (95% CI: 77.8-90.4%) (P<0.0001) for benign disease. With additional strict imaging criteria applied, the FFF sign had a specificity of 98.6% (95% CI: 94.9-99.8%) (P<0.0001) and a positive predictive value of 90.0% (95% CI: 68.3-98.5%). A positive FFF sign was predominately due to granulomatous disease (91%), mostly histoplasmosis (73%). A positive FFF sign combined with positive fungal serology (n=16) had a specificity of 100% for benign disease. The FFF sign predicts benign disease in patients with a lung nodule(s) and an FDG avid draining lymph node(s) that would otherwise be considered worrisome for cancer.

Entities:  

Keywords:  Histoplasmosis; granulomatous; lung cancer; lung nodule; positron emission tomography

Year:  2017        PMID: 29181268      PMCID: PMC5698614     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  14 in total

1.  Solitary pulmonary nodules differentiated by dynamic F-18 FDG PET in a region with high prevalence of granulomatous disease.

Authors:  Yu-Erh Huang; Hung-I Lu; Feng-Yuan Liu; Yu-Jie Huang; Meng-Chih Lin; Chih-Feng Chen; Pei-Wen Wang
Journal:  J Radiat Res       Date:  2012-02-25       Impact factor: 2.724

2.  Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society.

Authors:  Heber MacMahon; John H M Austin; Gordon Gamsu; Christian J Herold; James R Jett; David P Naidich; Edward F Patz; Stephen J Swensen
Journal:  Radiology       Date:  2005-11       Impact factor: 11.105

3.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging.

Authors:  T Bury; A Dowlati; P Paulus; J L Corhay; T Benoit; J M Kayembe; R Limet; P Rigo; M Radermecker
Journal:  Eur Respir J       Date:  1996-03       Impact factor: 16.671

4.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.

Authors:  Sung Shine Shim; Kyung Soo Lee; Byung-Tae Kim; Myung Jin Chung; Eun Jung Lee; Joungho Han; Joon Young Choi; O Jung Kwon; Young Mog Shim; Seonwoo Kim
Journal:  Radiology       Date:  2005-07-12       Impact factor: 11.105

5.  Positron emission tomography in the evaluation of pulmonary nodules among patients living in a coccidioidal endemic region.

Authors:  Nathaniel Reyes; Oluwole O Onadeko; Maria Del Carmen Luraschi-Monjagatta; Kenneth S Knox; Margaret A Rennels; Travis Kent Walsh; Neil M Ampel
Journal:  Lung       Date:  2014-05-07       Impact factor: 2.584

Review 6.  Value of whole-body FDG PET in management of lung cancer.

Authors:  Kotaro Higashi; Ichiro Matsunari; Yoshimichi Ueda; Ryosuke Ikeda; Jianfei Guo; Manabu Oguchi; Hisao Tonami; Itaru Yamamoto
Journal:  Ann Nucl Med       Date:  2003-02       Impact factor: 2.668

7.  Granulomatous disease: is it a nuisance or an asset during PET/computed tomography evaluation of lung cancers?

Authors:  Surya Chundru; Ching-yee Oliver Wong; Dafang Wu; Helena Balon; Jane Palka; Chih-Yung Chang; Marianne Gaskill; Cheng-Yi Cheng; Wen-Sheng Huang; Darlene Fink-Bennett
Journal:  Nucl Med Commun       Date:  2008-07       Impact factor: 1.690

Review 8.  PET/CT imaging in lung cancer: indications and findings.

Authors:  Bruno Hochhegger; Giordano Rafael Tronco Alves; Klaus Loureiro Irion; Carlos Cezar Fritscher; Leandro Genehr Fritscher; Natália Henz Concatto; Edson Marchiori
Journal:  J Bras Pneumol       Date:  2015 May-Jun       Impact factor: 2.624

Review 9.  The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases.

Authors:  Andor W J M Glaudemans; Erik F J de Vries; Filippo Galli; Rudi A J O Dierckx; Riemer H J A Slart; Alberto Signore
Journal:  Clin Dev Immunol       Date:  2013-08-21

Review 10.  PET/CT in the staging of the non-small-cell lung cancer.

Authors:  Fangfang Chao; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-07
View more
  2 in total

Review 1.  Spectrum of [18F]FDG-PET/CT Findings in Benign Lymph Node Pathology.

Authors:  Merissa N Zeman; Clare Green; Esma A Akin
Journal:  Mol Imaging Biol       Date:  2021-01-29       Impact factor: 3.488

Review 2.  Thoracic positron emission tomography: 18F-fluorodeoxyglucose and beyond.

Authors:  Timothy J Jaykel; Michael S Clark; Daniel A Adamo; Brain T Welch; Scott M Thompson; Jason R Young; Eric C Ehman
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.